BerGenBio
Clinical-stage biopharma that developed selective AXL kinase inhibitors for cancer.
BGBIO | OL
Overview
Corporate Details
- ISIN(s):
- NO0012921180 (+2 more)
- LEI:
- 213800TYYFXKYF3V2A23
- Country:
- Norway
- Address:
- MØLLENDALSBAKKEN 9, 5009 BERGEN
- Website:
- https://www.bergenbio.com/
- Sector:
- Manufacturing
Description
BerGenBio was a clinical-stage biopharmaceutical company focused on developing first-in-class selective AXL kinase inhibitors. The company's therapeutic candidates targeted AXL as a potential cornerstone of therapy for aggressive, advanced, and treatment-resistant cancers. In October 2025, BerGenBio completed a merger with Oncoinvent ASA, and the combined entity was renamed Oncoinvent.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-10-29 17:35 |
Merger of BerGenBio and Oncoinvent completed
|
English | 4.5 KB | ||
| 2025-10-29 07:00 |
BerGenBio and Oncoinvent - Last day of trading in the shares of Oncoinvent
|
English | 3.2 KB | ||
| 2025-10-28 10:42 |
BerGenBio ASA: Approval and publication of prospectus
|
English | 9.9 KB | ||
| 2025-10-24 08:00 |
BerGenBio and Oncoinvent - Key Dates for Completion of Merger
|
English | 9.4 KB | ||
| 2025-09-17 08:56 |
BerGenBio ASA: Updated Key Information related to the contemplated Rights Issue
|
English | 10.0 KB | ||
| 2025-09-17 08:55 |
BerGenBio ASA: Updated information regarding the contemplated Rights Issue and …
|
English | 3.6 KB | ||
| 2025-08-20 07:00 |
BerGenBio First half results 2025 - Attachment: H1_2025_Financial_report.pdf
|
English | 905.6 KB | ||
| 2025-08-20 07:00 |
BerGenBio First half results 2025
|
English | 5.4 KB | ||
| 2025-08-05 16:49 |
BerGenBio ASA - Updated key information related to the rights issue
|
English | 10.0 KB | ||
| 2025-08-04 13:40 |
BerGenBio ASA: Approval of the merger plan and the fully underwritten rights is…
|
Norwegian | 794.1 KB | ||
| 2025-08-04 13:40 |
BerGenBio ASA: Approval of the merger plan and the fully underwritten rights is…
|
English | 2.2 KB | ||
| 2025-07-03 14:53 |
BerGenBio ASA: Notice of Extraordinary General Meeting - Attachment: BerGenBio_…
|
Norwegian | 441.1 KB | ||
| 2025-07-03 14:53 |
BerGenBio ASA: Notice of Extraordinary General Meeting
|
English | 2.6 KB | ||
| 2025-06-30 22:30 |
BerGenBio ASA - Key information related to the rights issue
|
English | 10.0 KB | ||
| 2025-06-30 22:05 |
Announcement of fully underwritten rights issue - Attachment: Attachment_overvi…
|
English | 101.2 KB |
Automate Your Workflow. Get a real-time feed of all BerGenBio filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for BerGenBio
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for BerGenBio via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
